NCT06570915View on ClinicalTrials.gov

Daratumumab for T Cell ALL With MRD-positive After Standard Chemotherapy

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

December 1, 2025

Primary Completion Date

September 1, 2027

Study Completion Date

September 1, 2028

Conditions
ALL, Adult
Interventions
DRUG

Daratumumab Injection

Daratumumab was administered once a week at a dose of 16 mg/kg for a total of 4 times (Day1,8,15,22 ) in one cycle.

All Listed Sponsors
lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER